How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comPhase I/IIa First-in-Human Study of [212Pb]VMT01 Targeted Alpha-Particle Therapy for MC1R Positive Advanced Malignant Melanoma Dose
Description:
In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated in patients with unresectable and metastatic melanoma.
Sponsor:
Viewpoint Molecular Targeting
Contacts:
Markus Puhlmann, MDmpuhlmann@perspectivetherapeutics.com
319-665-2151
Government Study Link:
NCT05655312 - Click here to see study onClinicalTrials.gov
Share your feedback
Help us improve your experience